Quick Answer
TransMedics Group, Inc. reported Total Revenue of $605.49 million for fiscal year 2025.
TransMedics Group, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $605.49M +37.1% |
$441.54M +82.7% |
$241.62M +158.5% |
$93.46M +208.8% |
$30.26M +18.0% |
$25.64M +8.6% |
| Net Income | $190.29M +436.6% |
$35.46M +241.7% |
-$25.03M +30.9% |
-$36.23M +18.1% |
-$44.22M -53.8% |
-$28.75M +14.3% |
| Diluted EPS | $4.87 +382.2% |
$1.01 +231.2% |
-$0.77 +37.4% |
-$1.23 +23.1% |
-$1.60 -37.9% |
-$1.16 |
| Total Assets | $1.07B +32.9% |
$804.08M +13.9% |
$706.05M +154.8% |
$277.15M +105.5% |
$134.89M -11.3% |
$152.03M +44.4% |
| Cash and Equivalents | — | — | $394.81M +96.2% |
$201.18M +686.5% |
$25.58M +4.1% |
$24.58M +22.3% |
| Long-Term Debt | — | — | — | $58.70M +66.8% |
$35.20M +1.6% |
$34.66M +1.5% |
| Stockholders Equity | $473.10M +107.0% |
$228.60M +66.6% |
$137.20M -26.8% |
$187.38M +176.1% |
$67.85M -34.7% |
$103.89M +90.1% |
| R&D Expense | $69.06M +23.4% |
$55.97M +55.2% |
$36.05M +34.5% |
$26.81M +20.2% |
$22.30M +18.4% |
$18.83M -5.2% |
| Operating Income | $108.58M +189.6% |
$37.50M +230.5% |
-$28.73M +8.6% |
-$31.44M +20.3% |
-$39.43M -49.4% |
-$26.38M +10.9% |
| Gross Profit | $362.81M +38.4% |
$262.08M +70.1% |
$154.09M +136.1% |
$65.27M +208.5% |
$21.16M +27.2% |
$16.64M +20.0% |
| Shares Outstanding | 34.27M +1.9% |
33.62M +2.9% |
32.67M +1.6% |
32.14M +15.7% |
27.79M +2.3% |
27.18M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $143.82M | +32.2% | -8.6% |
| Net Income | September 30, 2025 | $24.32M | +476.8% | -30.3% |
| Diluted EPS | September 30, 2025 | $0.66 | +450.0% | -28.3% |
| Total Assets | September 30, 2025 | $946.03M | +20.4% | +6.2% |
| Cash and Equivalents | September 30, 2024 | $330.09M | -22.7% | -9.0% |
| Long-Term Debt | March 31, 2023 | $58.80M | +66.4% | +0.2% |
| Stockholders Equity | September 30, 2025 | $355.20M | +69.2% | +11.7% |
| R&D Expense | September 30, 2025 | $15.26M | +7.0% | -4.2% |
| Operating Income | September 30, 2025 | $23.30M | +493.9% | -36.3% |
| Gross Profit | September 30, 2025 | $84.58M | +39.0% | -12.4% |
| Shares Outstanding | September 30, 2025 | 34.14M | +1.7% | +0.3% |
- TransMedics Group, Inc. reported Total Revenue of $605.49 million for fiscal year 2025.
- TransMedics Group, Inc. showed an increase of +37.1% in Total Revenue compared to the prior fiscal year.
- TransMedics Group, Inc. reported Net Income of $190.29 million for fiscal year 2025.
- TransMedics Group, Inc. showed an increase of +436.6% in Net Income compared to the prior fiscal year.
- TransMedics Group, Inc. reported Diluted EPS of $4.87 per share for fiscal year 2025.
- TransMedics Group, Inc. showed an increase of +382.2% in Diluted EPS compared to the prior fiscal year.
- TransMedics Group, Inc. reported Total Assets of $1.07 billion for fiscal year 2025.
- TransMedics Group, Inc. showed an increase of +32.9% in Total Assets compared to the prior fiscal year.
- TransMedics Group, Inc. reported Cash and Equivalents of $394.81 million for fiscal year 2023.
- TransMedics Group, Inc. showed an increase of +96.2% in Cash and Equivalents compared to the prior fiscal year.
- TransMedics Group, Inc. reported Long-Term Debt of $58.70 million for fiscal year 2022.
- TransMedics Group, Inc. showed an increase of +66.8% in Long-Term Debt compared to the prior fiscal year.
- TransMedics Group, Inc. reported Stockholders Equity of $473.10 million for fiscal year 2025.
- TransMedics Group, Inc. showed an increase of +107.0% in Stockholders Equity compared to the prior fiscal year.
- TransMedics Group, Inc. reported R&D Expense of $69.06 million for fiscal year 2025.
- TransMedics Group, Inc. showed an increase of +23.4% in R&D Expense compared to the prior fiscal year.
- TransMedics Group, Inc. reported Operating Income of $108.58 million for fiscal year 2025.
- TransMedics Group, Inc. showed an increase of +189.6% in Operating Income compared to the prior fiscal year.
- TransMedics Group, Inc. reported Gross Profit of $362.81 million for fiscal year 2025.
- TransMedics Group, Inc. showed an increase of +38.4% in Gross Profit compared to the prior fiscal year.
- TransMedics Group, Inc. reported Shares Outstanding of 34.27 million shares for fiscal year 2025.
- TransMedics Group, Inc. showed an increase of +1.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: